TAC T-cells for the Treatment of HER2-positive Solid Tumors

Stopped early · Phase 1/Phase 2

Conditions studied: HER2 Positive Gastric Cancer, Metastatic HER2 Positive Gastroesophageal Junction Cancer

In brief

TAC01-HER2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor receptor 2 (HER2). TAC directs T-cells to the targeted antigen (HER2), and once engaged with the target, activates them via the endogenous T cell receptor. This is an open-label, multicenter Phase 1/2 study that aims to establish safety, maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D), pharmacokinetic profile and efficacy of TAC01-HER2 as a monotherapy, and in combination with pembrolizumab, in subjects with HER2 positive gastric and gastroesophageal adenocarcinoma.

Key facts

Study ID: NCT04727151
Run by: Triumvira Immunologics, Inc.
People needed: 28
Starts: 2021-04-19
Expected to finish: 2024-03-25
Last updated by the study team: 2025-06-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Written informed consent.
Age ≥ 18 years at the time of informed consent.
For Phase 1 and Phase 2:
Phase 1 monotherapy (completed): HER2 1+, 2+, 3+ by IHC by central laboratory confirmation
Phase 1 combination therapy and Phase 2: HER2 2+, 3+ by IHC and FISH by central laboratory confirmation
Histologically confirmed advanced, metastatic, unresectable solid tumors (regardless of PD-L1 expression levels; Phase 1 monotherapy) and histologically confirmed advanced, metastatic, unresectable gastric or esophageal adenocarcinoma (regardless of PD-L1 expression levels for Phase 1 combination therapy and Phase 2) after at least 2 prior lines of therapy (Phase 1) or after at least 2 and no more than 4 prior lines of therapy (Phase 2).
HER2+ incurable malignancies for which no standard-of-care HER2 targeted therapy exists may be enrolled regardless of the number of prior treatment lines, as long as in the opinion of the investigator the subject would be unlikely to tolerate or derive clinically meaningful benefit from other available treatment options.
For breast cancer subjects, both prior lines of therapy must have included HER2-targeted agents per current standard-of-care.
Subjects with solid tumors with genetic alterations and mutations (such as BRAF, BRCA, EGFR mutations, and ALK translocation) where approved targeted therapies were available to their specific cancers must have been previously treated with such approved therapies or refused such approved targeted therapy for their cancers prior to enrollment, or in the opinion of the investigator would be unlikely to tolerate or derive clinically meaningful benefit from these standard-of-care therapies.
Measurable disease per RECIST 1.1 at time of enrollment.
ECOG performance status of 0 or 1 at Screening.
Life expectancy of at least 12 weeks.
Adequate organ and bone marrow reserve function.
Recovery to Grade ≤1 or Baseline for any toxicities due to previous therapy.
Adequate vascular access for leukapheresis.
Negative pregnancy test and use of highly effective contraception.
Undetectable HBV viral load.
HCV viral load is undetectable.

You may not qualify if…

Intolerant to any component of TAC01-HER2.
Prior treatment with any of the following:
Adoptive cell transfer of any kind, including CAR T cells
Gene therapy
Investigational medicinal product within 5 half-lives or 21 days prior to leukapheresis, whichever is shorter.
Receipt of a live or live-attenuated vaccine within 30 days prior to study treatment.
Monoclonal antibody (mAb), including PD-1 and PD-L1, therapies within 21 days prior to leukapheresis.
Radiation within 28 days prior to enrollment. Palliative radiation is allowed up to 14 days prior to enrollment if non-irradiated lesions are present.
Chemotherapy or targeted small molecule therapy within 14 days prior to leukapheresis, or within 7 days prior to leukapheresis for erlotinib, gefitinib, afatinib, or crizotinib.
Colony stimulating factors, including granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), erythropoietin, and other hematopoietic cytokines, within 14 days prior to leukapheresis.
Immunosuppressive medication within 14 days or corticosteroid treatment < 72 hours prior to enrollment.
History or presence of clinically relevant central nervous system (CNS) pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis. (Brain metastasis - non-progressive or previously treated and currently stable - are permitted.)
Active inflammatory neurological disorders (e.g., Guillain-Barre Syndrome, amyotrophic lateral sclerosis, multiple sclerosis).
Active autoimmune disease (e.g., lupus, rheumatoid arthritis, Sjogren's syndrome) requiring systemic disease modifying agents in the past 2 years.
Active or uncontrolled hepatitis B or C (HCV ribonucleic acid [RNA] positive) infection or any history of or active human immunodeficiency virus (HIV) infection.
Uncontrolled, acute, or life-threatening bacterial, viral, or fungal infection. Subjects with ongoing use of prophylactic antibiotics, antifungals, or antivirals are eligible if no evidence of active infection.
Class III or IV heart failure (as defined by the New York Heart Association - NYHA), cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically significant cardiac disease within 6 months prior to Screening.
Cardiac arrhythmia not controlled by medical management.
Clinically significant thrombotic events within 6 months prior to leukapheresis and/or inability to stop anti-coagulation for at least 2 weeks prior to TAC01-HER2 infusion.
Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, non-metastatic squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
Pregnant or lactating.
As determined by the Investigator, any uncontrolled medical, psychological, familial, sociological, or geographical condition(s) that do(es) not permit compliance with the protocol.
Participation in or has participated in a study using an investigational device within 4 weeks prior to study treatment..
Has a history or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the subject's participation for the full duration of the study, such that it is not in the best interest of the subject to participate, in the opinion of the treating investigator.
Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.

Where it is running

Lurie Cancer Center - Northwestern University — Chicago, Illinois, United States
University of Chicago Comprehensive Cancer Center — Chicago, Illinois, United States
Dana Farber Cancer Institute — Boston, Massachusetts, United States
Rutgers Cancer Institute of New Jersey — Newark, New Jersey, United States
Roswell Park Comprehensive Cancer Center — Buffalo, New York, United States
Memorial Sloan Kettering Cancer Center — New York, New York, United States
University of Cincinnati Cancer Center — Cincinnati, Ohio, United States
Sidney Kimmel Cancer Center - Thomas Jefferson University — Philadelphia, Pennsylvania, United States
MD Anderson Cancer Center — Houston, Texas, United States
Princess Margaret Cancer Centre — Toronto, Ontario, Canada
Centre Hospitalier de l'Université de Montréal/Montreal Hospital University Center (CHUM) — Montreal, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.